Insider filing report for Changes in Beneficial Ownership
- Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
- Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13D
Under the Securities Exchange Act of 1934
|
Medinotec Inc. (Name of Issuer) |
COMMON STOCK, $0.001 PER SHARE PAR VALUE (Title of Class of Securities) |
58500G107 (CUSIP Number) |
Stavros G. Vizirgianakis C/O XTANT MEDICAL HOLDINGS, INC., 664 CRUISER LANE BELGRADE, MT, 59714 27 87 330 2301 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) |
04/16/2025 (Date of Event Which Requires Filing of This Statement) |
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the
Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).
SCHEDULE 13D
|
| CUSIP No. | 58500G107 |
| 1 |
Name of reporting person
Stavros G. Vizirgianakis | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
PF | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
SOUTH AFRICA
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
4,750,179.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
40.4 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
IN |
Comment for Type of Reporting Person:
(Item 13) Based on a total of 11,733,750 shares of the Issuer's common stock outstanding as of January 13, 2025 as stated in the Issuer's Form 10-Q for the quarter ended November 30, 2024 filed with the SEC on January 14, 2025.
SCHEDULE 13D
|
| Item 1. | Security and Issuer | |
| (a) | Title of Class of Securities:
COMMON STOCK, $0.001 PER SHARE PAR VALUE | |
| (b) | Name of Issuer:
Medinotec Inc. | |
| (c) | Address of Issuer's Principal Executive Offices:
NORTHLANDS DECO PARK, 10 NEW MARKET ST., STAND 299 AVANT GARDE AVENUE, JOHANNESBURG,
SOUTH AFRICA
, 2169. | |
Item 1 Comment:
Full address as follows: Northlands Deco Park | 10 New Market Street | Stand 299 Avant Garde Avenue | North Riding | Johannesburg | South Africa 2169. | ||
| Item 2. | Identity and Background | |
| (a) | Stavros G. Vizirgianakis | |
| (b) | C/O XTANT MEDICAL HOLDINGS, INC. 664 CRUISER LANE BELGRADE, MT 59714 | |
| (c) | The Reporting Person is currently a board member of the Company. The Company is located at Northlands Deco Park, 10 New Market Street, Stand 299 Avant Garde Avenue, North Riding, Johannesburg, South Africa 2169 | |
| (d) | No | |
| (e) | No | |
| (f) | Monaco | |
| Item 3. | Source and Amount of Funds or Other Consideration | |
The Reporting Person holds 4,750,179 shares of common stock, which were acquired on April 26, 2021 in connection with the issuance of 10,000,000 shares of common stock to the founding shareholders at 0.001 per share. | ||
| Item 4. | Purpose of Transaction | |
The purpose of this Schedule 13D is to report the Beneficial Ownership by the Reporting Person of 4,750,179 shares of common stock or 40.4% of the Issuer's issued and outstanding common stock as of January 13, 2025. The Reporting Person has no present plans or proposals which relate to or would result in any of the actions specified in clauses (a) through (j) of Item 4. The Reporting Person may, from time to time, determine to acquire additional Common Stock, to dispose of some or all of his Common Stock, discuss the Issuer's business, operations or other affairs with the Issuer's management, board of directors, shareholders, or others or take such other action as he deems appropriate. The Reporting Person reserves the right to change his intentions and adopt plans or proposals in the future that could result in any of the transactions specified in clauses (a) through (j) of Item 4, or any other transaction which the Reporting Person believes could enhance shareholder value. | ||
| Item 5. | Interest in Securities of the Issuer | |
| (a) | The Reporting Person is currently the beneficial owner of 4,750,179 shares of common stock of the Issuer, representing approximately 40.4% of the Issuer's common stock (based upon 11,733,750 outstanding shares of common stock as of January 13, 2025 as reported in the Company's Quarterly Report on Form 10-Q filed with the SEC on January 14, 2025). | |
| (b) | The Reporting Person has sole voting and dispositive power over the Shares identified in response to Item 5(a) above. | |
| (c) | Aside from the following, the Reporting Person has not effected any transactions in shares of common stock in the past 60 days. | |
| (d) | Not applicable. | |
| (e) | Not applicable. | |
| Item 6. | Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer | |
Other than as described in this Schedule 13D, the Reporting Person has no contracts, arrangements, understandings or relationships with any other person with respect to any securities of the Issuer. | ||
| Item 7. | Material to be Filed as Exhibits. | |
None | ||
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|